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PREAMBLE
The granting of staff privileges to physicians is an important
mechanism to ensure quality care. The Joint Commission
on Accreditation of Healthcare Organizations requires
that medical staff privileges be based on professional crite-
ria specified in medical staff bylaws. Physicians are charged
with defining the criteria that constitute professional com-
petence and with evaluating their peers accordingly. With
the evolution of transcatheter aortic valve replacement
(TAVR), an important opportunity arises for both cardiolo-
gists and surgeons to come together to identify the criteria
for performing these procedures. The Society for Cardio-
vascular Angiography and Interventions (SCAI), American
Association for Thoracic Surgery (AATS), American Col-
lege of Cardiology Foundation (ACCF), and the Society
of Thoracic Surgeons (STS) have, therefore, joined together
to provide recommendations for institutions to assess their
potential for instituting and/or maintaining a transcatheter
valve program. This article concerns TAVR. As TAVR is
in its infancy, there are few data on which to base this
consensus statement. Therefore, many of these recommen-
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Administration (FDA) having just approved the first gener-
ation of TAVR devices, the writing committee and partici-
pating societies believe that the recommendations listed in
this report serve as an appropriate starting point. In some
ways, these recommendations apply to institutions more
than to individuals. As there is a strong consensus that
these new valve therapies are best performed using
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applied at the institutional level. Partnering societies
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ACCF, and STS believe that adherence to these
recommendations will maximize the chances that these
therapies will become a successful part of the
armamentarium for treating valvular heart disease in the
United States. In addition, these recommendations will
hopefully facilitate optimum quality during the delivery of
this therapy, which will be important to the development
and successful implementation of future, less invasive
approaches to structural heart disease.
INTRODUCTION
Enabled by the development of new technologies, treat-
ment of valvular heart disease by transcatheter techniques
is becoming a favored approach of cardiac providers, result-
ing in less invasive treatment for patients previously treat-
able only with open heart surgery or, in many cases, not
treatable at all. Recognition from the medical community
of the applicability, effectiveness, and practicality of
catheter-based transcatheter valve therapies has further in-
creased interest in these treatments. Training program con-
tent, standards, credentialing, and board certifications for
cardiac surgical procedures and percutaneous coronary in-
tervention (PCI) are well developed, but no such structure
exists in the field of percutaneous structural or valvular
heart disease therapies. The purpose of this article is to out-
line criteria for operator and institutional requirements to
enable institutions and providers to participate responsibly
in this new and rapidly developing field.
The emergence of transcatheter aortic valve repair and
implantation as an alternative to traditional surgical ther-
apy for valvular diseases has been facilitated by innova-
tive devices, rapidly developing techniques, and careful
patient selection.1 The combination of interventional
skills, equipment, collaborative clinical management,
surgical approaches, techniques, and decision-making
distinguish the qualifications to participate in this field
as unique, as does the complexity of the patients requir-
ing these therapies.1-3 Given both the high-risk nature of
these catheter interventions and the availability of estab-
lished alternative treatment options using traditionalThe Journal of Thoracic and Carsurgical approaches, several considerations are important
for institutions and operators planning to implement
these new technologies.
Defining operator and institutional requirements for these
novel therapies is an important first step in ensuring their
optimal implementation.
Establishing a structural heart disease intervention ther-
apy program requires several key components (Tables 1
and 2). The defining principle is that this effort is a joint,
institutionally-based activity for cardiologists and cardiac
surgeons.1,4 Thus, the specialty that provides some of
these components will vary from program to program. A
transcatheter aortic valve replacement (TAVR) program
that uses only 1 specialty is fundamentally deficient, and
valve therapy programs should not be established without
this multidisciplinary partnership. Comprehensive
multidisciplinary teams (MDTs) are, therefore, required
for transcatheter valve therapies.
KNOWLEDGE BASE AND SKILLS
The critical cornerstone for establishing a transcatheter
valve program is the formal collaborative effort between in-
terventional cardiologists and cardiac surgeons. This ele-
ment is essential for establishing a transcatheter valve
program. No one individual, group, or specialty possesses
all the necessary skills for best patient outcomes.1,5 The
over-arching goal of these programs must be to provide
the best possible patient-centered care.1,6
As these are new techniques, the correlation between op-
erator experience and performance metrics for these proce-
dures has yet to be established. The current pool of trained
individuals is comprised predominantly of those who have
participated in industry-sponsored trials aimed at device
approval. Therefore, the translation of currently available
experiences with transcatheter valve therapies to the ‘‘real
world’’ has yet to be evaluated in the United States.
Several core concepts should be implemented for all phy-
sicians performing these procedures, irrespective of their
specialty background.7,8 They should all possess extensive
knowledge of valvular heart disease, including the natural
history of the disease, hemodynamics, appropriate diag-
nostics, optimal medical therapy, application and outcome
of invasive therapies, and procedural and perioperative care.9
The ability to interpret echocardiographic and other ra-
diographic images (obtained at baseline, during the proce-
dure, and follow-up) is critically important. MDTs and
procedural teams need to possess echocardiographic inter-
pretation skills for transthoracic and transesophageal stud-
ies. The use of 3-dimensional (3D) and 4-dimensional
echoes may evolve to become essential diagnostic tools.
Expertise in the interpretation of computed tomography
(CT) scans of the iliofemoral vessels, cardiac anatomy, as
well as aortic valvular anatomy, is critical for determining
patient eligibility and the approach for procedures.8,10diovascular Surgery c Volume 143, Number 6 1255
TABLE 1. Transcatheter aortic valve replacement: Criteria for new and existing programs
New programs Institutional interventional program 1000 cath/400 PCI per year*
TAVR interventionalist 100 Structural procedures lifetime or 30 left sided structural per year of which 60% should
be balloon aortic valvuloplasty
(Left sided procedures include EVAR, TEVAR, BALLOON AORTIC VALVE [BAV],
aortic valve [AV] and mitral valve [MV] prosthetic leak closures, and ventricular septal
defect [VSD] closures.) (Atrial septal defect/patent foramen ovale [ASD/PFO] closure
are not considered left sided procedures.)
Suitable training on devices to be used
Institutional surgical program 50 Total AVR per year of which at least 10 aortic valve replacement (AVR) should be high-
risk (STS score  6)
Minimum of 2 institutionally-based cardiac surgeons in program (more than 50% time at
hospital with surgical program)
TAVR surgeon 100 AVR career, at least 10 of which are ‘‘high-risk’’ (STS score 6) or 25 AVR per year or
50 AVR in 2 years and at least 20 AVR in last year prior to TAVR initiation
Experience with, and management of, peripherally inserted cardiopulmonary bypass
Experience with open retroperitoneal exposure of, and surgical intervention on, the iliac
arteries
Suitable training on devices to be used
Training Cardiologists must be board certified/eligible in interventional cardiology
Surgeons must be board certified/eligible in thoracic surgery
Additional operators who are trained or experienced in structural heart disease and
have unrestricted hospital privileges in structural procedures may also be part of
the interventional operating team with the interventional cardiologist and
cardiovascular surgeon
Existing programs Institutional Programs in existence>18 months: 30 TAVR (total experience)
Programs in existence<18 months: 2 per month
Training Cardiologists must be board certified/eligible in interventional cardiology
Surgeons must be board certified/eligible in thoracic surgery
Additional operators who are trained or experienced in structural heart disease, and
have unrestricted hospital privileges in structural procedures, may also be part of
the interventional operating team with the interventional cardiologist and
cardiovascular surgeon
*With acceptable outcomes for conventional procedures compared to NCDR benchmarks.
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tion between operator experience with specific procedures
and the skills necessary to perform transcatheter valve pro-
cedures, although there are some procedures that require
similar prerequisite skills such as balloon aortic valvulo-
plasty (BAV) for TAVR. There are, however, some core
concepts that professional societies have accepted as im-
portant for both facilities and operators.1,11,12 Minimum
training for specific procedures and devices will, for
the immediate future, be primarily dictated by FDA
approval requirements. Simulation is likely to play
a significant role in technical training and proficiency
maintenance for these evolving procedures.13-17 As these
procedures become integrated into mainstream care
delivery, the strategy for training will likely need to be
revised.1256 The Journal of Thoracic and Cardiovascular SurMinimum requirements for transcatheter valve therapies
include an understanding of basic radiation safety necessary
for optimal imaging, operator and patient exposure protec-
tion, and knowledge of the use of X-ray contrast agents,
which may not be standard in cardiac surgery training and
experience.
Training in the use of closed systems for hemodynamic
monitoring and contrast injections will result in optimal in-
tegration into catheterization laboratories and hybrid envi-
ronments. Catheter and wire skills, including knowledge
of the use of various techniques and the equipment available
to access complex anatomy and negotiating necessary vas-
cular and anatomic structures are required. Understanding
of the interplay of wires, catheters, and anatomy is required
for completion of these procedures. These skills can be ac-
quired in a variety of ways. Prior experience with a varietygery c June 2012
TABLE 2. Volume and outcomes for continued certification for both
new and existing TAVR programs applies to ‘‘inoperable’’
(PARTNER Cohort B) TAVR patients
Program volume of 20 TAVR per year or 40 per 2 years
30-day all-cause mortality<15%
30-day all-cause neurologic events including transient ischemic attack
(TIAs)<15%
Major vascular complication<15%*
>90% Institutional follow-up
60% 1-year survival rate for nonoperable patients (cohort b)—after the
program has been running for 2 years (2-year average)
Ongoing continuing medical education (CME) (or nursing/technologist
equivalent) of 10 hr per year of relevant material
All cases must be submitted to a single national database
*According to Valve Academic Research Consortium (VARC)-2 definitions.9a
Tommaso et al Clinical Guidelinesof interventional techniques is important. These include but
are not limited to:
 Coronary diagnostic procedures
 Coronary interventions
 Peripheral vascular diagnostic procedures
 Peripheral vascular interventions
 Balloon aortic, mitral, and pulmonic valve dilatation
 Stent implantation in right ventricle outflow tract and
pulmonary arteries
 Intra-aortic balloon pump (IABP), other cardiac support
device placement, including initiation of percutaneous
cardiopulmonary bypass
 Percutaneous ventricular assist device placement
 Endovascular aneurysm repair (EVAR) or thoracic endo-
vascular aortic repair (TEVAR) procedures
 Transseptal techniques
 Coronary sinus access
 Large vessel access and closure
Operators should also have experience with specific
catheter-based techniques required for valve interventions.
Similarly, surgeons should have experience with transapical
approaches for left ventricular assist device placement and
care of similar high-risk patients to perform transapical
TAVR.11,12,18 The experience of an interventionalist or
surgeon should be relevant to the transcatheter valve
procedure undertaken. In this document, attention will
focus on cardiac surgery and interventional cardiology
experience relevant to aortic valve intervention.
The concept of sterile technique must be completely un-
derstood and stringently applied to the delivery of transcath-
eter valve therapies. Interventionalists must understand and
be able to function in an environment that has more strin-
gent sterile technique requirements than are common in
catheterization laboratories. As one of the leaders of the
team performing these procedures, the interventionalist
must be able to enforce compliance with these standards.
These procedures may involve open or partially openThe Journal of Thoracic and Carsurgical components. Also, large devices that possess the
same risk of infection as conventional valve prostheses
will be implanted, especially for valve replacement proce-
dures. Operating theater standards for sterile technique
are, therefore, mandatory to ensure best patient outcomes.FACILITIES
The institution should have an active valvular heart dis-
ease surgical program with at least 2 institutionally-based
cardiac surgeons experienced in valvular surgery, and
should contain a full range of diagnostic imaging and ther-
apeutic facilities including:
1. Cardiac catheterization laboratory or hybrid operating
room (OR)/cath lab equipped with a fixed radiographic
imaging system with flat-panel fluoroscopy, offering
catheterization laboratory quality imaging. A biplane
unit may be advantageous, particularly for congenital
heart disease.
2. Noninvasive imaging
a. Echocardiographic laboratory. Transthoracic and
transesophageal echocardiographic capabilities with
sonographers and echocardiographers experienced
in valvular heart disease. Access to 3D echocardiog-
raphy is preferable.
b. Vascular laboratory (noninvasive) with vascular spe-
cialists capable of performing and interpreting vascu-
lar studies.
c. CT laboratory with CT technologists and specialists
who can acquire and interpret cardiac CT studies.
3. Physical space—The implantationsuitemusthaveasterile
environment that meets OR standards. Furthermore, it
must have sufficient space to accommodate the necessary
equipment for uncomplicated implantations aswell as any
additional equipment thatmay benecessary in the event of
complications. This includes space for anesthesiology,
echocardiography, and cardiopulmonary bypass equip-
ment andpersonnel.A specifically designedhybridOR in-
terventional suite is ideal; however, in the absence of such
a facility, the interventional cardiac suite should have:
a. Circulating heating, ventilation, and air conditioning
laminar flow diffusers (providing smooth, undis-
turbed air flow and usually placed directly over the
procedure table) to meet air requirements for surgery
rooms.
b. Asymmetrical/symmetrical 6-lamp 2 3 4 troffers (the
inverted, usuallymetal trough suspended from the ceil-
ing as a fixture for fluorescent lighting) to provide ade-
quate high-output lighting for surgical intervention.
c. Adequate number of power receptacles that meet sur-
gical equipment requirements.
d. Capability of running cardiopulmonary bypass appa-
ratus in the interventional suite.diovascular Surgery c Volume 143, Number 6 1257
Clinical Guidelines Tommaso et ale. Gas outlets for the anesthesia machine.
f. Adequate room size to accommodate the standard
equipment required in a cardiac catheterization labo-
ratory (eg, high-definition displays and monitors, O2
analyzer, defibrillator/resuscitation cart, O2 supply,
suction, compressed air, CO-oximeter, activated clot-
ting time analyzer)
g. Minimum room size of 800 square feet (74.3 m2)
to accommodate echocardiographic equipment,
sonographers, anesthesia equipment, emergency CT
surgical team and cardiopulmonary bypass equip-
ment (eg, surgeon, assistant, scrub tech, pump techs),
if needed.
4. Fungible equipment—The interventional suite should
stock a large variety of fungible equipment, including
various access kits, endovascular sheath and introducers
ranging from 4 to 26 F in various lengths, a wide range of
guide wires for various purposes, cardiac diagnostic and
interventional catheters, vascular closure devices, bal-
loon dilatation catheters ranging from 2 to 30 mm in di-
ameter and of various lengths and profiles, bare metal
and covered stents (eg, coronary and peripheral), occlu-
sive vascular devices, snares and other retrieval devices,
drainage catheters, and various implantable device sizes
with their delivery systems.
5. Postprocedure intensive care facility with personnel ex-
perienced in managing patients who have undergone
conventional open heart valve procedures.
6. Use of mobile C-arm imaging system in an OR is not ad-
equate.
7. HYBRID OR—The ‘‘2012 American College of Cardi-
ology Foundation Society for Cardiovascular Angiogra-
phy and Interventions Expert Consensus Document on
Cardiac Catheterization Laboratory Standards Update’’
will outline the specifications for a hybrid Cath Lab/
OR.18a Though this is preferable, it is not a prerequisite
since it is not available at many institutions
Most importantly, there must be dedication on the part of
the hospital to provide these services and support, both
financially and with no time constraints on the personnel
involved. A dedicated administrator as a member of the
team is necessary.
OTHER INSTITUTIONAL RESOURCES
For preprocedure and postprocedure care and joint for-
mal multidisciplinary patient consultation, adequate out-
patient clinical care facilities are necessary. Appropriate
office space for the medical, nursing, and technical per-
sonnel involved is also required, preferably in a central
setting. Ancillary testing facilities (ie, pulmonary func-
tion, echocardiography, vascular Duplex scanning, clini-
cal laboratory, multislice CT) should be of high quality1258 The Journal of Thoracic and Cardiovascular Surand able to accommodate the patient load on a timely
basis.
By their very nature, these complex procedures should
only be performed in institutions that currently and
routinely perform large volumes of surgical aortic valve
operations with outcomes that equal or exceed those
established nationally for similar procedures. Similarly,
only institutions with interventional cardiology programs
that have established and successful programs with BAV,
catheter closure of periprosthetic valvular leaks, insertion
of ventricular septal closure devices with outcomes that
equal or exceed those established nationally for similar
procedures should develop an integrated structural heart
MDT.
The institutional commitment required for a successful
program goes beyond the necessary space, personnel, and
specialized facilities set forth above. The complex and
time consuming preprocedure patient triage process and
the amount and intensity of postprocedure patient care after
discharge are very labor intensive for the physician and
nursing staff, as are the informed consents and communica-
tions with patients, families, and referring providers. In ad-
dition to supporting the core nursing and technical support
staff, arrangements between the institution and the physi-
cians need to be structured to reimburse physician efforts
dedicated to nonreimbursable hours of clinical care and
medical management of the program.
The complexity of transcatheter valve procedures and the
magnitude of institutional resources required are similar to
established heart transplant and cardiac assist device pro-
grams, where dedicated professionals, a minimum of infra-
structure, MDT, registered nurse/nurse practitioner (NP),
providers, coordinators, databases, and quality reporting
are essential for optimal patient outcomes.1 This concept
was endorsed by the Centers for Medicare and Medicaid
Services (CMS) through the establishment of certification
criteria for the use of heart transplantation and cardiac assist
devices in centers and, moreover, for eligibility for reim-
bursement of services provided. The same regulatory sys-
tem was applied to professionals providing these services.
Transcatheter valve treatment programs should undergo
a similar regulatory process with CMS endorsement. Cen-
ters should be approved for transcatheter aortic valve
programs based on a minimum number of cases per year,
and perioperative and 1-year outcomes above a minimum
threshold.
Long-term outcome reporting is obligatory, to track not
only survival, but also other parameters including peripro-
cedural complications (CVA, vascular, renal, infectious,
etc), aortic regurgitation, the need for reintervention, sub-
sequent surgery, and quality of life. This type of reporting
is essential, since long-term outcome goals for these new
procedures have not been established at this early stage.gery c June 2012
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TVT Registry) is mandatory.1
MULTI-DISCIPLINARY TEAM
The use of a team approach has been shown to improve
outcomes in these types of complex procedures.19 The
MDT necessary for a TAVR program is highlighted by the
collaboration between the interventional cardiologist and
cardiac surgeon.1 The MDT, however, goes well beyond
this collaboration, and must include key providers from
other physician groups (eg, anesthesiology, radiology, non-
invasive cardiology, intensive care). In addition to the indi-
vidual physicians, other components that extend to various
departments are necessary. The idea that the MDT is com-
prised of individual physicians working in a room perform-
ing the procedures is a superficial view that does not take
into account the level of resources necessary for a successful
valve therapy program. The interaction among specialists in
the MDT is fundamental, particularly for preprocedure pa-
tient evaluation and selection. It is equally fundamental that
the patient be at the very center of all discussions and
decision-making regarding the best therapy in her/his par-
ticular circumstance. While there is great excitement about
the application of transcatheter valve therapies, most of
these therapies will only be indicated for a small portion
of the population for the immediate future. Proper
decision-making and determination of best options for
any given patient require an evaluation by the MDT.20
On-site valve surgery is an essential component of any
valve therapy program. The requirement for on-site valve
surgery is based not only on the potential need for emer-
gency or ‘‘back-up’’ surgery for percutaneous patients but
more importantly on the quality of patient evaluation and
selection, decision-making, intraprocedure management,
and postprocedure care and outcomes.
A cardiac surgeon and an interventional cardiologist
must evaluate every case. Interplay between interventional
cardiologists and cardiac surgeons represent only part of the
benefit of the MDT.1 As noted above, additional critical
contributions are provided by cardiac anesthesiologists,
by imaging specialists in both cardiology and radiology,
and by the many people who extend beyond the physician
members of the team. The MDT is led by a core of physi-
cians from interventional cardiology, cardiac surgery, car-
diac anesthesiology, and intensive care and cardiac
imaging departments, along with congenital heart disease
specialists and surgeons, in some instances. Depending on
the institutional organization and the needs of the patient,
vascular surgery and interventional radiology departments
may also participate in the MDT. Additional team members
include NPs from all of these fields, research coordinators,
and a dedicated administrator.
The function of the MDT is essential in preprocedure pa-
tient selection, intraprocedure management and problemThe Journal of Thoracic and Carsolving, postprocedure management, postdischarge follow-
up, and outcome studies. During procedures, emergencies
or unanticipated needs may arise as a matter of course even
in the most straightforward situation. The immediate avail-
ability of MDT support to help with decision-making or
with therapy is essential. A clear definition of roles for differ-
ent specialties aswell as effective communication,whichmay
be different from that of conventional procedures, is critical
for successful outcomes. Difficult postprocedure courses
are common in the high-risk patients who comprise a large
part of the target population for both transcatheter and opera-
tive valve therapies. A team approach to problem solving in
this setting is critical. Another important part of patient man-
agement is the familiarity that the intensive care unit and the
monitored step-down floor staff have with the specific details
of each form of valve therapy. After the postprocedure man-
agement phase, long-term, posthospital follow-up for this se-
lect group of patients is also part of theMDT’s responsibility.
Planning for and resourcing this important phase of care is in-
cumbent on theMDT. Post approval registries (eg, STS/ACC
TVT Registry)1 will be required for many of the new trans-
catheter valve therapies, and, therefore, a data collection/
research unit within theMDT is another required component.
For sites with no prior trial experience in aortic transcath-
eter therapies, background experience from related proce-
dures is important. The surgical use of ventricular assist
device support or apical conduit therapy for aortic stenosis
or left ventricular apical venting during aortic aneurysm
procedures provides excellent experience for management
of apical access for TAVR. For transcatheter procedures
that do not directly involve the surgeon as a procedure
operator, the role of the cardiac surgeon remains critically
important. The surgeon has many roles and is often a patient
advocate and/or referring physician, and is a necessary sci-
entific study participant in all of these device applications.
The surgeon is familiar with established standards of surgi-
cal care for application in transcatheter therapies and is
frequently in charge of assessing high-risk patients for
catheter-based therapy as an alternative to surgery. In a valve
therapy program, neither the surgeon nor the cardiologist
should be in charge of the assessment, but rather the
MDT. In all transcatheter aortic procedures, the interven-
tionalist and the surgeon should be present for the critical
portions of the procedure.
Another mechanism for promoting a team approach that
involves both surgeons and cardiologists is split or shared
physician reimbursement for these procedures, which this
writing group strongly endorses. This important principle
will ensure that surgeons and cardiologists participate
jointly in performing procedures, and that each patient
receives the best and most patient-centered treatment.
The MDT should meet formally as a group on a regular
basis (aside from the usual ‘‘cath conference’’) to review
all patients referred for procedures, performance of recentdiovascular Surgery c Volume 143, Number 6 1259
Clinical Guidelines Tommaso et alprocedures (to discuss both favorable and unfavorable out-
comes), and follow-up of prior procedures.
FUNCTION OF THE MDT
Programmatic success depends on the ability of the MDT
to function effectively in the best interest of a given patient.
To do so, the MDT must work cohesively through the pro-
cesses of patient selection, procedural planning, procedural
conduct, periprocedural care, and longitudinal follow-up.1
Through each phase of this continuum, the individual skills
of the MDT members should be brought to bear on the
process.
The procedural success of transcatheter valve therapies
begins with patient selection. Given the complexity of the
decision-making process surrounding these procedures, it
is necessary that all MDT members provide objective input
and judgments from the outset of a patient evaluation.1 In
order that true informed consent be obtained, the patient
must remain at the center of the deliberations of the MDT
at all times, and must be involved in the discussions regard-
ing her/his therapeutic approach and goals. The patient
selection process may be initiated by use of regularly
scheduled patient selection conferences attended by all
MDT members. Such conferences are analogous to trans-
plant patient selection committee meetings, and provide
a venue in which patient-specific data and imaging are for-
mally presented and discussed by the MDT. The respective
expertise of each discipline represented among MDT
members may then be synthesized into a patient-specific
recommendation.
Direct patient evaluation by cardiologists and cardiac
surgeons may be accomplished jointly and, if possible, si-
multaneously in a venue such as a multidisciplinary valve
program clinic. Not only does such a clinic provide conve-
nience for the many patients who are elderly and fragile, but
it also provides an opportunity for cardiac surgeons and car-
diologists to jointly examine and evaluate complex patients.
In so doing, the expertise and judgment of both disci-
plines may be woven into a patient-specific decision. The
participation of anesthesiologists in these clinics may also
be useful.
Following the decision that a given patient is an appropri-
ate candidate for TAVR, the procedure must then be care-
fully planned. Cardiac surgical teams are familiar with,
and routinely use the concept of, ‘‘preprocedure briefings’’
before complex cardiac surgical operations. In such brief-
ings, all teammembers (ie, surgeons, anesthesiologists, per-
fusionists, nurses, and technicians) discuss the intended
procedure, including the steps of the planned procedure,
the specific tools and equipment needed (beyond those typ-
ically used), the possible complications that may arise dur-
ing the course of the procedure, and the contingency plans
that will be implemented should the unexpected occur.1
All members of the team may then initiate the planned1260 The Journal of Thoracic and Cardiovascular Surprocedure with a common understanding of its conduct
and what will happen if the plan needs to change.
As integral members of the MDT, the cardiologist, car-
diovascular surgeon, and the catheterization team will par-
ticipate actively in this preprocedure planning and MDT
briefing, which is so important for the procedural success
of transcatheter valve therapies. During the procedure,
emergency situations and unexpected needs may arise.
The immediate availability of MDT physician support in
emergency decision-making and therapy is essential. It is,
therefore, important that the roles of the various specialties
be clearly delineated during preprocedure planning.
Patients who undergo transcatheter valve therapies are
often elderly and frail with multiple comorbidities. Postpro-
cedure care of such patients may be difficult and entail the
management of multiple organ system dysfunctions. In
many cases, the initial postprocedure care should be pro-
vided in an intensive care setting. A team approach to the
care of these patients and to problem solving is important
and should include physicians skilled in critical care medi-
cine. Once in-patients are able to leave the intensive care en-
vironment, they should be attended by a unit specializing in
the care of patients with cardiac diseases, and this unit
should be equipped with telemetry-monitored beds. Again,
a team approach is important for success. The team of phy-
sicians, nurses, occupational and physical therapists, and
other members must have an understanding of the patho-
physiology of the particular valve condition, as well as
the nuances of care for patients who have undergone cardiac
surgery and interventional cardiology procedures.
Procedural success of transcatheter valve therapies must
be determined via longitudinal outcomes. Long-term fol-
low-up of these patients is an important element of the
MDT approach. Post-FDA approval registries (eg, STS/
ACC TVT Registry) will be required for most transcatheter
valve therapies.1 Therefore, a long-term relationship be-
tween the patient and the MDT must be established to
undertake the needed alterations in medical therapy, serial
echocardiographic imaging, and monitoring of devices.
Likewise, changes in patient functional status, heart failure
class, potential device-related complications, and other
such conditions must be carefully tracked. Avalve program
clinic can provide a venue for this type of long-term
follow-up.
The postmarket surveillance of transcatheter valve
devices will be an extremely important function of the
MDT. Participation in device-specific registries (eg, STS/
ACC TVT Registry) can be challenging and requires an
institutional infrastructure and commitment that includes
experienced data managers with a background in cardiac
disease, funding, office space, and computer resources. It
requires a clinical research unit with rigorous attention to
detail, and the collection of accurate data as an integral
part of the function of the MDT.gery c June 2012
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ATRANSCATHETER VALVE PROGRAM AND
MAINTENANCE OF COMPETENCE
An important issue in the establishment of a transcatheter
valve program is the clinical or referral base for ensuring an
adequate number of patients to provide for the viability of
a program. The requirements for the establishment of
a successful transcatheter valve program are described in
Table 1.
Once chosen for participation as TAVR programs, either
as existing programs, or as new programs, to maintain ongo-
ing approval for participation, sites will be monitored to en-
sure that they continue to satisfy both the volume and
outcomes criteria as described in Table 2.
Unlike the experience with PCI, where data attest to the
relationship between the volume of procedures and out-
comes, there are little or no data on which to draw conclu-
sions as to the volume–outcome relationship for TAVR.
Therefore, these recommendations are constructed to: (1)
ensure patient safety, (2) demonstrate that there is a commit-
ment on the part of the institution to the structural heart dis-
ease program, and (3) use existing volume as a surrogate for
an established valve program to ensure adequate patient
volumes for the establishment of a sustainable and high-
quality transcatheter valve program. As experience grows
and more data become available, these recommendations
will undoubtedly be refined.AORTIC VALVE REPLACEMENT
Surgical aortic valve replacement is the treatment of
choice for patients with severe aortic valve disease.1 How-
ever, a significant percentage of those patients are not of-
fered the procedure or simply refuse to undergo it on the
basis of excessive risks, both real and perceived.21 It is in
this context that the possibility of transcatheter aortic valve
implantation has become a reality for patients outside of the
United States. Furthermore, the cohort B results of the
PARTNER (Placement of Aortic Transcatheter) trial (non-
operable patients) would indicate that medical therapy, in-
cluding BAV, should be reserved only for patients who do
not qualify for the procedure on the basis of their anatomy
or clinical characteristics.22 Considering the reports of suc-
cessful transcatheter treatment of aortic valve stenosis using
balloons23 and subsequent reports of poor long-term out-
comes due to early restenosis,24 the idea of developing
a transcatheter aortic valve was a logical progression. Initial
animal studies25 and subsequent human implantations have
led to the progressive development of this technology.
Results from the PARTNER trial using the Edwards Sa-
pien Valve (Edwards Lifesciences, Irvine, Calif), the first
randomized trial of this technology, have established its
place as a treatment of severe symptomatic aortic steno-
sis.22-26 The trial consisted of 2 arms: cohort A (n ¼ 699),The Journal of Thoracic and Carthe high risk surgical group, which randomized patients to
surgical aortic valve replacement or TAVR, and cohort B
(n ¼ 358), the nonsurgical group randomized to medical
therapy, which could include valvuloplasty or TAVR.
Results from the noninferiority cohort A group showed
a 1 year all-cause mortality of 26.8% in the surgical arm
and 24.2% in the TAVR arm, a hazard ratio (HR) (95%
CI) of 0.93 (0.7, 1.22), which met the noninferiority end-
point, P ¼ .001 (for a noninferiority margin of 7.5 percent-
age points). There were differences in outcomes between
the groups, the most worrisome being a higher incidence
of stroke or transient ischemic attack (TIA) at 30 days
and at 1 year in the TAVR arm (at 30 days: 5.5% vs
2.4%, P ¼ .04 and at 1 year: 8.3% vs 4.3%, P ¼ .04).
The need for a new permanent pacemaker was not different
between the groups, 5.7% in the surgical arm versus 5.0%
in the TAVR arm, P¼ .68. In cohort B, TAVR was found to
be superior to medical therapy with an all-cause mortality at
1 year of 50.7% in the medical arm versus 30.7% in the
TAVR arm, HR (95% CI) 0.54 (0.58, 0.78, P<.001). These
findings suggest that it is necessary to treat 5 patients to pre-
vent 1 death.27 PARTNER II, which uses a new, lower pro-
file delivery system, is in the early stages of patient
recruitment. To date, there are no randomized data regard-
ing the CoreValve prosthesis (Medtronic, Minneapolis,
Minn) but it has received the CE mark in Europe, as has
the Sapien valve.
Registry data appear to show favorable hemodynamic
outcomes and acceptable mortality.28,29 In this large
multicenter registry consisting of 14 centers reporting on
663 consecutive patients,29 procedure success was 98%
with a procedural mortality of 0.9%. Thirty-day mortality
was 5.4% and 15.0% at 1 year. Stroke during the procedure
and at 1 year was 1.2% and 2.5%, respectively. The re-
quirement for a permanent pacemaker was 19.1% at
1 year, a rate similar to other registries reporting outcomes
using this valve. Independent predictors of mortality at 30
days included conversion to open heart surgery (odds ratio
[OR], 38.68), cardiac tamponade (OR, 10.97), major access
site complications (OR, 8.47), left ventricular ejection
fraction < 40% (OR, 3.51), prior balloon valvuloplasty
(OR, 2.87), and diabetes mellitus (OR, 2.66). Predictors
of late mortality (30 days to 1 year) included prior stroke
(HR, 5.47), post procedural paravalvular leak is  2þ
(HR, 3.79), prior acute pulmonary edema (HR, 2.70), and
chronic kidney disease (HR, 2.53). The CoreValve US Piv-
otal Trial is currently randomizing patients in a similar fash-
ion to the PARTNER trial and should yield additional
important data on this valve.
RESEARCH/REGISTRY
FDA clearance of a novel valve repair or replacement
prosthesis does not guarantee that the device will continue
to demonstrate long-term efficacy equal to currentlydiovascular Surgery c Volume 143, Number 6 1261
Clinical Guidelines Tommaso et alavailable options, or that its application will be limited to
the initially approved patient subsets. Postmarket studies or-
ganized through individual institutions or multicenter study
groups and registries managed by industry and professional
societies are essential for ensuring continued short-term
safety, and for determining long-term efficacy. Only with
such data can we consider application of new valve prosthe-
ses to a wider patient population outside the boundaries of
the study groups examined during FDA trials. Centers that
incorporate transcatheter-based therapies into their practice
absolutely must participate in a cardiac surgery or cardiol-
ogy national database such as the STS National Database,
Northern New England Cardiac Disease Study Group,
American College of Cardiology’s National Cardiovascu-
lar Data Registry, or an equivalent database.30-32 These
databases facilitate continued analysis of early outcomes
on a national level; however, most do not permit analysis
of results beyond the 30-day window, mandating the
development of implant registries with patient consent,
permitting late follow-up for survival and valve-related
complications and reinterventions. These valve repair
and replacement procedures should be registered in data-
bases capable of providing both acute outcome and long-
term follow-up data.
Early postprocedure morbidity and mortality analyses,
while important for initial and continued implant safety
assessment, are not sufficient to evaluate the efficacy of
valve repair or replacement prostheses. Studies on long-
term follow-up survival and, more importantly, structural
valve degeneration, and the need for reintervention, are es-
sential. Recent attempts to link the STS National Database
to an administrative survival database (Social Security
Death Master File) or to CMS Medicare data have been
promising; however, survival data alone will not be suffi-
cient for transcatheter valve registries (eg, STS/ACC TVT
Registry33). Risk adjustment using only administrative
data is challenging and may be more important in this
highly complex patient population. Transcatheter valve reg-
istries must incorporate late assessment of structural valve
degeneration and the need for late reoperation or reinterven-
tion. Long-term function data is also essential before appli-
cation of new valve repair or replacement technology can be
considered for lower risk and younger patients. Clinicians
must be careful not to extrapolate outcomes generated dur-
ing FDA trials to patients that do not reasonably approxi-
mate the trial study populations. At present, it is not
acceptable for clinicians to apply ‘‘off label’’ transcatheter
techniques to patients who are otherwise excellent candi-
dates for conventional valve repair or replacement outside
the confines of a randomized, controlled trial or, at a mini-
mum, multicenter, national, prospective studies.
The potential negative impact of a valve prosthesis recall,
in regards to the increased risk associated with reoperative
surgery for a permanent implant, far outweighs that1262 The Journal of Thoracic and Cardiovascular Surassociated with the removal of a pharmacologic agent
from the market.34 Thus, the allocation of adequate funding
to allow complete follow-up studies is essential, including
financial support from industry, the FDA, National Insti-
tutes of Health, CMS, and professional societies, with sci-
entific oversight distanced from industry and potential
conflicts of interest. Postmarket surveillance governed
solely by industry self-regulation can be of dubious value.
In a 2005 editorial, Eugene Blackstone cautioned, ‘‘Indus-
try has not developed a viable mechanism for dealing
with ‘bad news,’ the disclosure of which often leads to the
demise of the company.’’35 The Interagency Registry for
Mechanically Assisted Circulatory Support exemplifies
a potentially efficient model that could be emulated by pro-
fessional societies for monitoring transcatheter inventions
during the next decade, during which durability data will
be generated.36
Transcatheter valve repair or replacement devices are
unique in that an understanding not only of early risk, but
also of long-term durability, is essential for determining
the appropriate patient subgroups for these therapies. In
our opinion, it is the responsibility of professional societies
to ensure adequate long-term data monitoring and provide
oversight and guidance to industry on the expectations for
continuedmonitoring beyond the FDA approval phase of de-
vice development and implementation. Individual centers
are also responsible for critically evaluating their own expe-
rience, through local and regional quality improvement ini-
tiatives, and for participating in national databases and
registries (eg, STS/ACCTVTRegistry) that facilitate contin-
ued safety and efficacy in the assessment of novel, and, as
yet, unproven, therapeutic options. Components of a na-
tional/international registry should include preoperative
risk factors and valve assessment, intraoperative details,
early postoperative morbidity, and late follow-up including
survival, need for reintervention, functional class, device-
related complications, and late assessment of valve perfor-
mance. It is inappropriate to perform these novel and
innovative procedureswithout the institutional infrastructure
to ensure adequate early data collection and later follow-up.
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